HealthyPhase 1NCT00983099
Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects
A Phase 1 study testing Neramexane in people with Healthy, run by Merz Pharmaceuticals GmbH at 1 site in United States.
Trial summary
Part 1 (single dose) Primary parameters Area under the plasma concentration curve from zero to infinity [AUC0-inf] and observed maximum plasma concentration [Cmax] of Japanese and Caucasian subjects for each dose group If at least 20% of the Japanese or of the Caucasian subjects have an area under the plasma… Read more about this study
- Who is it for?
- Ages 20 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Neramexane
- Type of treatment
- Pill or oral medicine
- How many people
- 56 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2009to Sep 2010
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and female subjects
- Caucasian (Part 1 only) or Japanese origin
- Japanese subjects must have a Japanese passport, Japanese grandparents and parents and not have lived outside of Japan for more than 5 years
- Aged 20 to 55 years (inclusive)
- Body weight between 50 and 90 kg (inclusive) with BMI ranging from 18.0 to 28.0 kg/m2 (inclusive) Japanese females may have a body weight of at least 45 kg (inclusive) with BMI ranging from 17.0 to 28.0 kg/m2 (inclusive)
- Females must have a negative urine pregnancy test at screening and on Day -1 for Part 1 and on Day 1 for Part 2
Show all 11Show fewer
- Subjects must be willing to use one of the following methods of contraception from the first dose of trial medication until completion of follow-up procedures.
- All subjects must agree to use condom and spermicide.
- Male subjects without vasectomy (with documentation of azoospermia) must assure that their female partners uses another form of contraception such as non hormonal IUD, diaphragm.
- Female subjects of childbearing potential must agree to use an effective method of birth control such as sexual abstinence, vasectomised partner, non hormonal IUDs or double contraception methods (e.g., condom with spermicide cream) from Screening until one month after last application of study drug.
- Willing and able to give written informed consent after having been informed of the requirements and the restrictions of the study
Who cannot join
- Subjects who have taken part in the drug administration phase of the single dose part are excluded from participation in the multiple dose part of the study and vice versa
- Any clinically relevant finding on medical history or, physical examination affecting subject's safety or the study objectives
- Any disease or condition, which could influence the physiological absorption, distribution and metabolic turnover (e.g. endocrine diseases, febrile conditions, severe infections, acute inflammations, chronic diarrhoea, chronic vomiting, gastrointestinal disease or surgery of the gastrointestinal tract, including cholecystectomy); appendectomy older than 6 months is allowed
- Prior history or present evidence of clinically significant metabolic, renal, hepatic, pulmonary or cardiovascular disease, CNS disorders or disturbances of bleeding (hemorrhagic diathesis), diagnosis of malignancy, polyneuropathy or psychiatric disorder, organ transplantation
- Any clinically relevant abnormal laboratory value (haematology, clinical chemistry, urinalysis) or laboratory values which in the discretion of the investigator and the Merz scientific expert might affect subject's safety or the study objectives
- Positive serology for human immunodeficiency virus [HIV] (HIV1/HIV2 antibodies), hepatitis B surface antigen [HBsAg], antibodies against hepatitis C virus [anti-HCV]
Show all 33Show fewer
- Clinically relevant abnormalities in the 12-lead ECG which in the discretion of the investigator and the Merz scientific expert might affect the study objectives
- Presence or history of clinically relevant allergy or a known or suspected hypersensitivity to Neramexane, Memantine or Amantadine and/or its study medication excipients and to quinine hydrochloride (slight seasonal hay fever is allowed as long as the season does not meet the study period)
- History of alcohol or drug dependence
- Alcohol consumption averaging more than 40 g alcohol (4 units) daily (28 units per week) within the last year for males and more than 20 g (2 units) daily within the last year for females
- Regular caffeine consumption averaging more than 5 cups of coffee or equivalent (500mg caffeine) per day within the last year
- Smoking more than 5 cigarettes per day or equivalent (use of snuff, nicotine replacement chewing tobacco)
- Refusal or inability to eat the meals provided by the clinic (e.g. vegetarian)
- Nursing mother
- Woman planning pregnancy during the course of the trial
- Evidence or suspicion that the subject might not comply with the study directives and/or that he/she is not reliable or trustworthy
- Evidence or suspicion that the subject is not willing or unable to understand the information that is given to him/her as part of the informed consent, in particular regarding the risks and discomfort to which he/she would agree to be exposed
- Subjects who are imprisoned or are lawfully kept in an institution
- Employees or direct relatives of an employee of the CRO or Merz Pharmaceuticals
- Systolic blood pressure <90 mm Hg or >140 mm Hg or diastolic blood pressure <50 mm Hg or > 95 mm Hg in supine position
- Pulse rate < 45 or > 100 beats per minute [bpm]
- Use of any prescribed drugs in the 4 weeks prior to the first administration of the IMP
- Regular use of over-the-counter [OTC] drugs (except paracetamol, maximum 1 g/day) in the 4 weeks prior to the first administration of the IMP or at least 10 half lives, whichever is longer
- Occasional use of OTC drugs (except paracetamol, maximum 1 g/day) in the 2 weeks prior to the (first) administration of the IMP
- Females taking hormonal contraceptives
- Participation in another clinical study of any IMP within 2 months prior to the first administration of IMP
- History of blood loss or donation of blood or plasma exceeding 450 ml within the last 3 months before first administration of IMP
- Acute illness in the past 14 days before administration of IMP (Day 1)
- Fever (oral > 37.5 °Celsius or 99.5 °Fahrenheit, respectively) in the last 8 days before Day 1 as reported by history or on Day 1
- Alcohol intake within the last 48 hours prior to the (first) administration of the IMP and a positive alcohol breath test on Screening and Day-1 for Part 1 and on Day 1 for Part 2
- Intake of recreational drugs within the last 4 weeks prior to first administration of IMP on Day 1 and a positive urine test for drugs of abuse on screening, Day -1 for Part 1 and Day 1 for Part 2
- Consumption of xanthine containing food or beverages within the last 48 hours prior to the first administration of the IMP
- Consumption of herbs/fruits that can have an influence on pharmacokinetics such as St. Johns wort, grapefruits or grapefruit juice within the last 72 hours prior to the first administration of the IMP
Trial locations and contacts
1 site in 1 country.
United States1 site
California Clinical Trials
Glendale, California, 91206
About this study
Part 1 (single dose)
Primary parameters
Read more
- Area under the plasma concentration curve from zero to infinity [AUC0-inf] and observed maximum plasma concentration [Cmax] of Japanese and Caucasian subjects for each dose group
- If at least 20% of the Japanese or of the Caucasian subjects have an area under the plasma concentration curve extrapolation [AUCextrap%] >20% relative to AUC0-inf for one of the dose groups area under the plasma concentration curve from zero to the last measurable concentration [AUC0- tz] becomes primary parameter for Japanese and Caucasian subjects for all of the dose groups. In this case AUC0-tau will become a secondary parameter
Secondary parameters and derived values from statistical analysis
- Dose proportionality and linearity in Japanese subjects
- Ratios (Japanese vs. Caucasian subjects) of AUC0-∞ and Cmax for each dose group
- Dose normalized AUC [AUC0-inf,norm], dose normalized Cmax [Cmax,norm], AUC0- tz, time of occurrence of Cmax [tmax], apparent terminal half life [t½], mean residence time [MRT], apparent (oral) total plasma clearance [CLtot/f], apparent volume of distribution during the terminal disposition phase [Vz/f], AUCextrap%, apparent terminal disposition rate constant [λz], weight corrected AUC0-inf, weight corrected AUC0-tz, weight corrected Cmax, weight corrected CLtot/f, cumulative amount of excreted Neramexane into urine [Ae0-tz], fraction of orally administrated drug excreted into urine [fe/f], renal clearance [CLR] and apparent non-renal clearance [CLNR/f]
- Safety and tolerability
Other parameters
- Pharmacogenetics
- Amount of N-OH Neramexane excreted in urine [Ae0-tz] if a validated method will be available at the time of analysis
- Metabolite determination (N-OH Neramexane) in plasma and urine, optional (may be analyzed and evaluated if a validated method will be available at the time of analysis)
- Endogenous creatinine clearance [CLCR], amount of excreted creatinine into urine per hour [AeCR,hr]
- Evaluation of further metabolites will be described in detail in the Statistical Analysis Plan
- Conditions
- Healthy
- Being tested
- Neramexane
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeramexaneDrug
single and multiple dose, tablets, oral
What is being measured
The primary outcome is the main question the study is designed to answer.
Determination of plasma concentration after single and multiple dose
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2009 (estimated)
- Study startSep 2009
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00983099
- Sponsor's protocol ID
- MRZ 92579/NA/1006
- Status last verified
- Apr 2011
- First submitted
- 18 Sep 2009
- Last updated
- 15 Apr 2011
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects
- ClinicalTrials.gov ID
- NCT00983099
- Acronym / sponsor ID
- MRZ 92579/NA/1006
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Merz Pharmaceuticals GmbHIndustry (pharma, biotech, devices)
- Study start
- Sep 2009
- Primary completion
- Sep 2010 (actual)
- Study completion
- Sep 2010 (actual)
- First posted
- 23 Sep 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Part 1 (single dose)
Primary parameters
- Area under the plasma concentration curve from zero to infinity [AUC0-inf] and observed maximum plasma concentration [Cmax] of Japanese and Caucasian subjects for each dose group
- If at least 20% of the Japanese or of the Caucasian subjects have an area under the plasma concentration curve extrapolation [AUCextrap%] >20% relative to AUC0-inf for one of the dose groups area under the plasma concentration curve from zero to the last measurable concentration [AUC0- tz] becomes primary parameter for Japanese and Caucasian subjects for all of the dose groups. In this case AUC0-tau will become a secondary parameter
Secondary parameters and derived values from statistical analysis
- Dose proportionality and linearity in Japanese subjects
- Ratios (Japanese vs. Caucasian subjects) of AUC0-∞ and Cmax for each dose group
- Dose normalized AUC [AUC0-inf,norm], dose normalized Cmax [Cmax,norm], AUC0- tz, time of occurrence of Cmax [tmax], apparent terminal half life [t½], mean residence time [MRT], apparent (oral) total plasma clearance [CLtot/f], apparent volume of distribution during the terminal disposition phase [Vz/f], AUCextrap%, apparent terminal disposition rate constant [λz], weight corrected AUC0-inf, weight corrected AUC0-tz, weight corrected Cmax, weight corrected CLtot/f, cumulative amount of excreted Neramexane into urine [Ae0-tz], fraction of orally administrated drug excreted into urine [fe/f], renal clearance [CLR] and apparent non-renal clearance [CLNR/f]
- Safety and tolerability
Other parameters
- Pharmacogenetics
- Amount of N-OH Neramexane excreted in urine [Ae0-tz] if a validated method will be available at the time of analysis
- Metabolite determination (N-OH Neramexane) in plasma and urine, optional (may be analyzed and evaluated if a validated method will be available at the time of analysis)
- Endogenous creatinine clearance [CLCR], amount of excreted creatinine into urine per hour [AeCR,hr]
- Evaluation of further metabolites will be described in detail in the Statistical Analysis Plan
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
Who may qualify
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Healthy male and female subjects
- Caucasian (Part 1 only) or Japanese origin
- Japanese subjects must have a Japanese passport, Japanese grandparents and parents and not have lived outside of Japan for more than 5 years
- Aged 20 to 55 years (inclusive)
- Body weight between 50 and 90 kg (inclusive) with BMI ranging from 18.0 to 28.0 kg/m2 (inclusive) Japanese females may have a body weight of at least 45 kg (inclusive) with BMI ranging from 17.0 to 28.0 kg/m2 (inclusive)
Key exclusion criteria (33 listed)
- Subjects who have taken part in the drug administration phase of the single dose part are excluded from participation in the multiple dose part of the study and vice versa
- Any clinically relevant finding on medical history or, physical examination affecting subject's safety or the study objectives
- Any disease or condition, which could influence the physiological absorption, distribution and metabolic turnover (e.g. endocrine diseases, febrile conditions, severe infections, acute inflammations, chronic diarrhoea, chronic vomiting, gastrointestinal disease or surgery of the gastrointestinal tract, including cholecystectomy); appendectomy older than 6 months is allowed
- Prior history or present evidence of clinically significant metabolic, renal, hepatic, pulmonary or cardiovascular disease, CNS disorders or disturbances of bleeding (hemorrhagic diathesis), diagnosis of malignancy, polyneuropathy or psychiatric disorder, organ transplantation
- Any clinically relevant abnormal laboratory value (haematology, clinical chemistry, urinalysis) or laboratory values which in the discretion of the investigator and the Merz scientific expert might affect subject's safety or the study objectives
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neramexanesingle and multiple dose, tablets, oral | Drug | – |
Primary outcome
Determination of plasma concentration after single and multiple dose
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2011.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Neramexane in people with Healthy, run by Merz Pharmaceuticals GmbH at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Apr 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determination of plasma concentration after single and multiple dose (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2011.